| scholarly article | Q13442814 |
| P2093 | author name string | Lakshmi Bhagat | |
| Dong Yu | |||
| Ekambar R Kandimalla | |||
| Nicola La Monica | |||
| Daqing Wang | |||
| Sudhir Agrawal | |||
| Tim Sullivan | |||
| P2860 | cites work | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects | Q38029146 |
| Current and emerging systemic treatment strategies for psoriasis | Q38039491 | ||
| CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation | Q38296546 | ||
| Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation | Q38327702 | ||
| Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling. | Q38335694 | ||
| Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation | Q38352355 | ||
| Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines | Q39577031 | ||
| G-rich DNA suppresses systemic lupus. | Q40370427 | ||
| Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity | Q40703529 | ||
| Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. | Q40858228 | ||
| Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance | Q42273902 | ||
| Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies | Q43262628 | ||
| Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs | Q46911101 | ||
| Suppressive oligonucleotides protect against collagen-induced arthritis in mice | Q47596728 | ||
| Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice | Q56897860 | ||
| A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease | Q61853102 | ||
| Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity | Q73324232 | ||
| In VivoPharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous Guanosines | Q73488159 | ||
| Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside | Q73867128 | ||
| Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages | Q74613271 | ||
| DNA and RNA autoantigens as autoadjuvants | Q79663762 | ||
| Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms | Q79946741 | ||
| Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity | Q82288145 | ||
| Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9 | Q84339569 | ||
| Regression of systemic lupus erythematosus after development of an acquired toll-like receptor signaling defect and antibody deficiency | Q84483456 | ||
| Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice | Q84960461 | ||
| Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs | Q24644853 | ||
| The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors | Q27860900 | ||
| Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha | Q28265144 | ||
| TLR8 deficiency leads to autoimmunity in mice | Q28292240 | ||
| Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide | Q29619485 | ||
| Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity | Q30829935 | ||
| Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. | Q33395050 | ||
| TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus | Q33902262 | ||
| TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus | Q34241004 | ||
| Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis | Q34312767 | ||
| 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents | Q34368468 | ||
| Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. | Q34396739 | ||
| Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. | Q34566135 | ||
| Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding | Q34647633 | ||
| Antisense and/or immunostimulatory oligonucleotide therapeutics | Q34790452 | ||
| Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles | Q34980516 | ||
| Interferon alpha as a primary pathogenic factor in human lupus | Q35603587 | ||
| The discovery and development of belimumab: the anti-BLyS-lupus connection | Q35691272 | ||
| Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. | Q35963017 | ||
| Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies | Q36052460 | ||
| Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus | Q36246166 | ||
| Interferon pathway activation in systemic lupus erythematosus | Q36319618 | ||
| Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus | Q36403653 | ||
| DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo | Q37270799 | ||
| Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. | Q37758263 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| The role of antimalarial agents in the treatment of SLE and lupus nephritis | Q37947108 | ||
| TLR7 and TLR9 in SLE: when sensing self goes wrong | Q37995556 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| P304 | page(s) | 3947-3961 | |
| P577 | publication date | 2013-02-08 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. | |
| P478 | volume | 41 |
| Q94547384 | A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation |
| Q38733975 | Advances in Antiviral Therapies Targeting Toll-like Receptors |
| Q98386176 | Advances in oligonucleotide drug delivery |
| Q38227972 | Advances in understanding the role of type I interferons in systemic lupus erythematosus |
| Q90594140 | Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes |
| Q39154516 | Cellular uptake and trafficking of antisense oligonucleotides |
| Q47146788 | Danger of frustrated sensors: Role of Toll-like receptors and NOD-like receptors in aseptic and septic inflammations around total hip replacements |
| Q38182971 | Emerging role of endosomal toll-like receptors in rheumatoid arthritis |
| Q38561435 | Immune-mediated pathology in Duchenne muscular dystrophy |
| Q34999938 | Novel drugs targeting Toll-like receptors for antiviral therapy |
| Q35253499 | Plastid-LCGbase: a collection of evolutionarily conserved plastid-associated gene pairs |
| Q38823065 | Recent progress in the development of Toll-like receptor (TLR) antagonists |
| Q89621507 | Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis |
| Q37708368 | Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle |
| Q37258447 | Scavenging nucleic acid debris to combat autoimmunity and infectious disease |
| Q34451758 | Targeting of type I interferon in systemic autoimmune diseases |
| Q61884090 | The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia |
| Q37210936 | The delivery of therapeutic oligonucleotides |
| Q49961986 | Therapeutic Targeting of Long Non-Coding RNAs in Cancer |
| Q35745585 | Toll-Like Receptor 9-Mediated Inflammation Triggers Alveolar Bone Loss in Experimental Murine Periodontitis |
| Q34650870 | Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. |
| Q35848152 | Toll-like receptors: potential targets for lupus treatment |
| Q38925152 | Toll-like receptors: promising therapeutic targets for inflammatory diseases |
| Q33852174 | Type I interferon in the pathogenesis of lupus |
| Q35690771 | Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells |
Search more.